This early-phase trial tests a new drug called ADI-PEG 20 added to two standard chemotherapy drugs (venetoclax and azacitidine) for people with acute myeloid leukemia (AML). The study includes 38 adults with either relapsed/refractory AML or newly diagnosed AML who cannot have in…
Phase: PHASE1 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC